BUSINESS

• Remitch OD Tablets Approved in Thailand: Toray/Meiji Pharma
  July 20, 2023

• More Crestor Generics Now on Equal Footing with Originator
  July 20, 2023

• Anthony Mallet Tapped as Servier Japan Chief
  July 19, 2023

• Astellas Becomes 1st Japan Pharma to Sue US Govt over IRA
  July 19, 2023

• Roche Group Sues Biogen over Actemra Biosimilar
  July 18, 2023

• Meiji’s Stelara Biosimilar Accepted for EU Review
  July 18, 2023

• Zolbetuximab Accepted for EMA Review in CLDN18.2 Gastric Cancer: Astellas
  July 18, 2023

• Nichi-Iko to Discontinue 258 Products, Largest Number Yet
  July 14, 2023

• Gilead Japan Building Sales Force to Prep for Full Oncology Entry: Chief
  July 14, 2023

• Enhertu Adds HER2 Low Breast Cancer Nod in China
  July 14, 2023

• Daiichi Sankyo Espha Rolls Out Follow-On AG for Maintate
  July 13, 2023

• Organon to Succeed Bepricor Distribution from Daiichi Sankyo in Japan
  July 13, 2023

• Astellas’ Iveric Bio Acquisition Completed
  July 13, 2023

• Generic Makers, Industry, and Govt Must Join Hands to Build Long-Term Stable Supply System: Towa Chief
  July 13, 2023

• Meiji to Develop Lineup Unaffected by Price Revisions, Bolster Earnings from New Drugs/Generics in Focus Areas
  July 12, 2023

• SanBio to Ax 22 Jobs in US, Focus on Work towards Japan Cell Therapy Launch
  July 12, 2023

• RaQualia’s Acid Reducer Tegoprazan Launched in Indonesia
  July 12, 2023

• JCR Grabs German OK for Launch of Global PI/II for MPS IIIA Drug
  July 12, 2023

• Eisai’s Alzheimer’s Skipper to Retire after Full Leqembi Approval
  July 12, 2023

• Astellas Bags Rights to 4DMT’s Gene Therapy Vector for Eye Diseases
  July 12, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 137
• 138
• 139
• 140
• 141
• 142
• 143
• 144
• 145
• …
• Next ›
• 最終 »